Coloplast A/S
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Its extensive reach spans Denmark, the ...
Latest News
2 days ago · seekingalpha.com
Coloplast A/S (CLPBY) Q4 2026 Earnings Call TranscriptColoplast A/S (CLPBY) Q4 2026 Earnings Call Transcript
2 days ago · reuters.com
Coloplast pares back China operations as market recovery remains elusiveColoplast pares back China operations as market recovery remains elusive
3 months ago · seekingalpha.com
Coloplast A/S (CLPBY) Q3 2026 Earnings Call TranscriptColoplast A/S (CLPBY) Q3 2026 Earnings Call Transcript
3 months ago · reuters.com
Coloplast expects Kerecis wound-care unit to return to growth in 2027, CFO saysMedical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused sales in outpatient settings to fall sharply, its finance chief told Reuters on Tuesday.
3 months ago · seekingalpha.com
Coloplast Might Have Found Its BottomColoplast remains a 'Buy,' trading ~20% below intrinsic value despite recent struggles and special charges. Organic growth was 6% in Q2-25/26, but reported results were impacted by a DKK 3 billion Kerecis impairment and currency headwinds. Management guides for 5–6% organic revenue growth and 5% EBIT growth in FY25/26, but targets 7–8% annual organic growth and 20%+ ROIC by FY29/30.
Earnings
Add to Watchlist
Select watchlists to add or remove CLPBY